Investment Thesis
Assembly Biosciences demonstrates exceptional revenue growth of 153.5% YoY with improving profitability metrics, but remains deeply unprofitable with a net margin of -110.5% and negative operating cash flow of -$22.1M. With only $31.1M in cash against ~$22.1M quarterly burn, the company has limited runway (~1.4 quarters) and must achieve profitability or secure additional capital immediately.
Strengths
- Exceptional revenue growth of 153.5% YoY indicating strong market traction and commercial execution
- Significant improvement in net loss trajectory with +84.8% YoY improvement, suggesting path toward profitability
- Strong balance sheet with $198.6M stockholders' equity and minimal leverage (0.00x debt/equity), providing financial flexibility
Risks
- Negative operating cash flow of -$22.1M with cash runway of only ~1.4 quarters at current burn rate, creating imminent liquidity pressure
- Unsustainable unit economics with $8.2M revenue against $22.1M operating cash burn, indicating business model not yet viable at scale
- Unprofitable operations with net margin of -110.5% and operating margin of -138.4%, dependent on continued revenue acceleration and cost control to survive
Key Metrics to Watch
- Quarterly operating cash flow trend and path to cash flow breakeven
- Cash burn rate relative to revenue growth acceleration
- Gross margin profile and ability to achieve operating leverage as revenue scales
Financial Metrics
Revenue
8.2M
Net Income
-9.1M
EPS (Diluted)
$-0.54
Free Cash Flow
-22.1M
Total Assets
235.5M
Cash
31.1M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-138.4%
Net Margin
-110.5%
ROE
-4.6%
ROA
-3.9%
FCF Margin
-269.3%
Balance Sheet & Liquidity
Current Ratio
6.65x
Quick Ratio
6.65x
Debt/Equity
0.00x
Debt/Assets
15.7%
Interest Coverage
-0.82x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-16T08:37:26.984488 |
Data as of: 2026-03-31 |
Powered by Claude AI